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Background: Coronary artery spasm (CAS) is a major cause of myocardial ischemia.
However, the incidence and clinical prognosis of diffuse CAS compared with focal
CAS has not been fully investigated. We compared diffuse CAS with focal CAS in
patients (pts) with vasospastic angina based on 3-year clinical outcomes.
Methods: A total of 2,797 consecutive pts without signiﬁcant coronary artery disease
(CAD) who underwent Acetylcholine (Ach) provocation test were enrolled between
Nov. 2004 and Oct. 2010. Patients were divided into three groups according to Ach
test results and spasm extent (CAS negative; n¼1,188, Diffuse CAS,  20mm;
n¼1,344, Focal CAS, < 20mm; n¼265).
Results: Baseline characteristics were similar between diffuse and focal groups.
Angiographically, the diffuse group showed higher incidence of multi-vessel spasm
(39.2% vs. 10.1%, p<0.01) and ECG changes (6.7 vs. 3.3%. p¼0.03), whereas the
focal group had more myocardial bridges (24.3 vs. 40.8%, p<0.01). Three-year
clinical outcomes including mortality, cardio & cerebro-vascular disease and recurrent
chest pain were similar between the two groups. When respectively compared with
CAS negative group, only diffuse CAS was shown to be an independent predictor of
recurrent chest pain (6.7% vs. 3.7%, p<0.01), even after adjustment using propensity
score matching (OR; 1.63, 95% C.I; 1.08-2.46).
Conclusion: In this study, diffuse CAS was associated with adverse 3-year clinical
outcomes. Therefore, intensive anti-anginal management and close clinical follow up
would be needed for pts who showed diffuse CAS during Ach provocation test.P
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Background: Chronic total occlusion (CTO) intervention is still challenging because
of the limited procedural success rate and high target failure. The impact of percu-
taneous coronary intervention (PCI) for CTO in the left anterior descending artery
(LAD) is not clear. We evaluated the 12-month clinical outcomes between PCI and
optimal medical therapy (OMT) for LAD-CTO patients.
Methods: A total of 218 consecutive CTO patients were divided into 2 groups ac-
cording to treatment strategy; PCI group (n¼117) and OMT group (n¼101). 12-month
clinical outcomes were compared between the two groups.
Results: At baseline, the OMT group had a higher prevalence of elderly, congestive
heart failure, left main disease, multivessel disease, multivessel CTO, LCX-CTO,
RCA-CTO, and well-developed collaterals (grade 2), whereas the PCI group had a
higher prevalence of current smokers. Clinical outcomes at 12 months after baseline
adjustment by multivariate analysis showed similar major hard endpoints including
mortality, myocardial infarction, revascularization and major adverse cardiac events
(Table).
Conclusion: In our study, PCI seems to have no beneﬁt over OMT in left anterior
descending artery chronic total occlusion. Long-term follow up with a larger study
population will be necessary for further evaluation.TCTAP A-180
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Background: It has been reported that signiﬁcant endothelial dysfunction or clinically
evident vasospasm can be associated with drug-eluting stents (DESs). However, the
impact of DES associated coronary artery spasm (CAS) on 3-year clinical outcomes in
patients (pts) with vasospastic angina has not been fully elucidated.R/High Risk Patients: Diabetes, Heart Failure, Renal Failure, Others S51
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(<70%) who underwent the Acetylcholine (Ach) test were enrolled between Nov
2004 and Oct 2010. DES-associated spasm was deﬁned as signiﬁcant CAS in prox-
imal or distal to previously implanted DES site at follow up angiography with Ach
test. Patients were divided into two groups: (DES-CAS; n¼108, CAS; n¼1,878). For
adjustment, propensity score matching (PSM) was done (C-statistics¼0.766, DES-
CAS; n¼102, CAS; n¼102).
Results: Baseline characteristics were worse in the DES-CAS group. After PSM, both
baseline characteristics and the Ach test results were balanced except higher incidence
of diffuse CAS and ECG change in the DES-CAS group. In 3-year clinical outcomes
before and after adjustment, the DES-CAS group showed higher incidence of coro-
nary revascularization, recurrent chest pain and major adverse cardiac events
(MACEs, Table).
Conclusion: In this study, DES associated CAS was related to higher incidence of
adverse 3-year clinical outcomes. Special caution should be exercised in this particular
subset of pts.TCTAP A-181
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Background: Coronary artery spasm (CAS) is a major cause of myocardial ischemia.
However, long-term clinical outcomes of CAS are largely unknown. We investigated
predictors of recurrent chest pain in patients (pts) with vasospastic angina based on 3-
year clinical outcomes.
Methods: A total of 2,797 consecutive pts without signiﬁcant coronary artery (CAD)
disease who underwent Acetylcholine (Ach) provocation test were enrolled between
Nov 2004 and Oct 2010. We investigated predictors of recurrent chest pain following
medical therapy.
Results: Ach test revealed 1,609 (57.5%) CAS positive pts [male; n¼823 (51.1%),
age; 55.0 years (interquartile, 47.5-63.2)]. Baseline characteristics included hyper-
tension [n¼ 663 (41.2%)], diabetes [n¼193 (11.9%)], dyslipidemia [n¼241 (14.9%)],
current smokers [n¼395 (24.5%)] and current alcoholics [n¼556 (34.5%)]. Ach
provocation test showed the incidence of myocardial bridge [n¼434 (26.9%)], base-
line CAS [n¼ 495 (30.7%)], diffuse CAS [n¼ 1344 (83.5%)] and multi-vessel spasm
[n¼ 555 (34.4%)]. After 3 years, recurrent chest pain [n¼102 (6.3%)] was the most
common clinical event. Other events included all-cause death [n¼3 (0.1%)], cardiac
death [n¼2 (0.1%)], myocardial infarction [n¼3 (0.1%)], percutaneous coronary
intervention [n¼3 (0.1%)] and cerebrovascular accidents [n¼3 (0.1%)]. Multivariate
analysis showed dyslipidemia (OR; 1.75, 95% C.I; 1.07-2.85, p¼0.025) and baseline
CAS (OR; 1.91, 95% C.I; 1.26-2.88, p¼0.002) were independent predictors of
recurrent chest pain (Table).
Conclusion: Dyslipidemia and baseline CAS were predictors of recurrent chest pain
in 3-year clinical outcomes. Therefore pts who have dyslipidemia or show baseline
CAS should managed by intensive anti-anginal management and close clinical
follow up.S52 JACC Vol 63/12/Suppl S j April 22–25, 2014 j TCTAP AbstractsTCTAP A-182
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Background: Hyperuricemia is a well-known risk factor for diabetes mellitus(DM)
and other cardiovascular diseases, but the relationship between hyperuricemia and the
development of new-onset DM is not clear. We evaluated the impact of hyperuricemia
on the development of new-onset DM based on 5-year cumulative clinical outcomes
in Asian patients.
Methods: A total of 3,274 patients who did not have DM were enrolled. New-onset
DM was deﬁned as having a fasting blood glucose 126mg/dL or HbA1c 6.5%.
Hyperuricemia was deﬁned as uric acid 7.0 mg/dL. Baseline characteristics between
the hyperuricemia and control groups were matched with propensity score match-
ing(PSM, C-statistics¼0.731). 5-year cumulative incidence of new-onset DM was
compared between the two groups.
Results: At baseline, patients in the hyperuricemia group showed a higher prevalence
of male gender, hypertension and dyslipidemia. The hyperuricemia group had higher
levels of basal insulin, HOMA-IR, triglyceride and lower levels of HDL-C. Devel-
opment of new-onset DM was higher in the hyperuricemia group (13.5% vs. 7.9%,
p<0.001). After PSM, baseline characteristics were well balanced (C-statics¼0.731).
After adjustment with cox-regression analysis, hyperuricemia remained to be a in-
dependent predictor of new-onset DM (OR 1.72, 95% CI 1.01 - 2.94, p¼0.045,
ﬁgure).
Conclusion: Hyperuricemi was shown to be an independent predictor of new-onset
DM. Therefore it may be suggested that uric acid levels should be included in the
prediction of DM and patients with hyperuricemia may beneﬁt from measures to
reduce the uric acid./POSTER/High Risk Patients: Diabetes, Heart Failure, Renal Failure, Others
